サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：免疫抑制薬の世界市場：予測（2022年～2028年）
市場調査レポート
商品コード
1123243

免疫抑制薬の世界市場：予測（2022年～2028年）

Global Immunosuppressive Drug Market Research and Forecast 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 125 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.53円
免疫抑制薬の世界市場：予測（2022年～2028年）
出版日: 2022年08月01日
発行: Orion Market Research
ページ情報: 英文 125 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の免疫抑制薬の市場規模は、予測期間（2022年～2028年）中に14.2%のCAGRで成長すると予想されています。世界各地での臓器移植率の増加、臓器移植における組織工学の採用の増加、臓器交換の需要の増加は、免疫抑制薬市場の成長に大きく寄与しています。

当レポートでは、世界の免疫抑制薬市場について調査分析し、市場概要、競合情勢、市場分析、企業プロファイルなど、体系的な情報を提供しています。

目次

カテゴリー：医薬品 1. レポート概要

  • 調査方法とツール
  • 市場の内訳
    • セグメント別
    • 地域別

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向

第3章 競合情勢

  • 主要企業分析
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の開発
  • 主要戦略分析

第4章 市場決定要因

  • 促進要因
  • 抑制要因
  • 機会

第5章 市場セグメンテーション

  • 用途別
    • 心臓移植
    • 腎臓移植
    • 肝移植
    • 肺移植
    • その他（骨髄移植）
  • 薬剤クラス別
    • カルシニューリン阻害剤
    • 抗増殖剤
    • mTOR阻害剤
    • ステロイド
    • その他
  • 薬剤タイプ別
    • 特許取得済
    • ジェネリック

第6章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • その他アジア太平洋地域
  • 世界のその他の地域

第7章 企業プロファイル

  • Abbvie Inc.
  • Astellas Pharma Inc
  • Biocon Ltd.
  • Bristol-Myers Squibb Co.
  • Cadila Healthcare Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Intas Pharmaceuticals Ltd（Accord Healthcare Ltd.）
  • LGM Pharma, LLC
  • Mylan NV
  • Novartis AG（Sandoz）
  • Pfizer Inc.
  • Sanofi SA
  • Taj Pharmaceuticals Ltd.
  • Topas Therapeutics GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Veloxis Pharmaceuticals, Inc.
図表

LIST OF TABLES

  • 1. GLOBAL IMMUNOSUPPRESSIVE DRUG MARKET BY APPLICATION, BY DRUG TYPE RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027($ MILLION)
  • 2. GLOBAL HEART TRANSPLANT MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 3. GLOBAL KIDNEY TRANSPLANT MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 4. GLOBAL LIVER TRANSPLANT MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 5. GLOBAL LUNGS TRANSPLANT MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 6. GLOBAL OTHER ORGAN TRANSPLANT MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 7. GLOBAL IMMUNOSUPPRESSIVE DRUG MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2020-2027($ MILLION)
  • 8. GLOBAL CALCINEURIN INHIBITOR MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 9. GLOBAL ANTIPROLIFERATIVE AGENT MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 10. GLOBAL MTORINHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 11. GLOBAL IMMUNOSUPPRESSIVE DRUG MARKET RESEARCH, AND ANALYSIS BY DRUG TYPE, 2020-2027($ MILLION)
  • 12. GLOBAL GENERIC DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 13. GLOBAL PATENTED DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 14. GLOBAL STEROIDS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 15. GLOBAL IMMUNOSUPPRESSIVE DRUG MARKET APPLICATION AND DRUG TYPE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
  • 16. NORTH AMERICAN IMMUNOSUPPRESSIVE DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 17. NORTH AMERICAN IMMUNOSUPPRESSIVE DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027($ MILLION)
  • 18. NORTH AMERICAN IMMUNOSUPPRESSIVE DRUG MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2020-2027($ MILLION)
  • 19. NORTH AMERICAN IMMUNOSUPPRESSIVE DRUG MARKET RESEARCH AND ANALYSIS BY DRUGTYPE, 2020-2027($ MILLION)
  • 20. EUROPEAN IMMUNOSUPPRESSIVE DRUG MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2020-2027($ MILLION)
  • 21. EUROPEAN IMMUNOSUPPRESSIVE DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 22. EUROPEAN IMMUNOSUPPRESSIVE DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027($ MILLION)
  • 23. EUROPEAN IMMUNOSUPPRESSIVE DRUG MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027($ MILLION)
  • 24. ASIA-PACIFIC IMMUNOSUPPRESSIVE DRUG MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2020-2027($ MILLION)
  • 25. ASIA-PACIFIC IMMUNOSUPPRESSIVE DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 26. ASIA-PACIFIC IMMUNOSUPPRESSIVE DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027($ MILLION)
  • 27. ASIA-PACIFIC IMMUNOSUPPRESSIVE DRUG MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2020-2027($ MILLION)
  • 28. ASIA-PACIFIC IMMUNOSUPPRESSIVE DRUG MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027($ MILLION)
  • 29. REST OF THE WORLD IMMUNOSUPPRESSIVE DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 30. REST OF THE WORLD IMMUNOSUPPRESSIVE DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027($ MILLION)
  • 31. REST OF THE WORLD IMMUNOSUPPRESSIVE DRUG MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2020-2027($ MILLION)
  • 32. REST OF THE WORLD IMMUNOSUPPRESSIVE DRUG MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2020-2027($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL IMMUNOSUPPRESSIVE DRUG MARKET SHARE BY APPLICATION, 2020 VS 2027 (%)
  • 2. GLOBAL IMMUNOSUPPRESSIVE DRUG MARKET SHARE BY DRUG TYPE, 2020 VS 2027 (%)
  • 3. GLOBAL IMMUNOSUPPRESSIVE DRUG MARKET SHARE BY DRUG CLASS, 2020 VS 2027 (%)
  • 4. GLOBAL IMMUNOSUPPRESSIVE DRUG MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 5. GLOBAL HEART TRANSPLANTMARKET RESEARCH AND ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 6. GLOBAL KIDNEY TRANSPLANT MARKET RESEARCH AND ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 7. GLOBAL LIVER TRANSPLANT MARKET RESEARCH AND ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 8. GLOBAL OTHER ORGAN TRANSPLANT MARKET RESEARCH AND ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 9. GLOBAL LUNGS TRANSPLANT MARKET RESEARCH AND ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 10. GLOBAL CALCINEURIN INHIBITOR MARKET RESEARCH AND ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 11. GLOBAL ANTIPROLIFERATIVE AGENT MARKET RESEARCH AND ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 12. GLOBAL MTOR INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 13. GLOBAL STEROIDS MARKET RESEARCH AND ANALYSIS BY REGION, 2020 VS 2027 (%)
  • 14. GLOBAL GENERIC IMMUNOSUPPRESSIVE DRUG MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 15. GLOBAL PATENTED IMMUNOSUPPRESSIVE DRUG MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 16. US IMMUNOSUPPRESSIVE DRUG MARKET SIZE, 2020-2027($ MILLION)
  • 17. CANADA IMMUNOSUPPRESSIVE DRUG MARKET SIZE, 2020-2027($ MILLION)
  • 18. GERMANY IMMUNOSUPPRESSIVE DRUG MARKET SIZE, 2020-2027($ MILLION)
  • 19. UK IMMUNOSUPPRESSIVE DRUG MARKET SIZE, 2020-2027($ MILLION)
  • 20. FRANCE IMMUNOSUPPRESSIVE DRUG MARKET SIZE, 2020-2027($ MILLION)
  • 21. SPAIN IMMUNOSUPPRESSIVE DRUG MARKET SIZE, 2020-2027($ MILLION)
  • 22. ITALY IMMUNOSUPPRESSIVE DRUG MARKET SIZE, 2020-2027($ MILLION)
  • 23. RUSSIA IMMUNOSUPPRESSIVE DRUG MARKET SIZE, 2020-2027($ MILLION)
  • 24. CHINA IMMUNOSUPPRESSIVE DRUG MARKET SIZE, 2020-2027($ MILLION)
  • 25. JAPAN IMMUNOSUPPRESSIVE DRUG MARKET SIZE, 2020-2027($ MILLION)
  • 26. INDIA IMMUNOSUPPRESSIVE DRUG MARKET SIZE, 2020-2027($ MILLION)
  • 27. LATIN AMERICA IMMUNOSUPPRESSIVE DRUG MARKET SIZE, 2020-2027($ MILLION)
  • 28. MIDDLE EAST AFRICA IMMUNOSUPPRESSIVE DRUG MARKET SIZE, 2020-2027($ MILLION)
目次
Product Code: OMR2018397

Immunosuppressive Drug Market Share, Growth, Competitive Analysis By Application (Heart Transplant, Kidney Transplant, Liver Transplant, Lungs Transplant, and other), By Drug Class (, Calcineurin Inhibitor, Antiproliferative Agent, mTOR Inhibitors, Steroids and other), By Drug Type (Patented and Generic) Forecast Period 2021-2027

The global immunosuppressive drug Market is growing at a significant CAGR of 14.2% during the forecast period. The major factors that are augmenting the growth of the immunosuppressive drug market include the increasing transplant rate of the organ all across the globe. The Immunosuppressive drug is used at the end-stage of organ transplants such as after the transplant of the kidney, heart, and liver. The drug is provided so that it can reduce the risk of organs getting rejected by the immune system of the human body. The increasing demand for organ replacement as well as the growing adoption of tissue engineering in organ transplant is significantly contributing to market growth. Adopting new medication options such as scleroderma treatment and increasing usage of tissue engineering are the factors that brought new opportunities to the Immunosuppressive drug market. However, certain factors are restraining the growth of the market such as the high cost of the drug as well as a shortage of organ donors for transplant.

Segmental Outlook

The market is segmented on the basis of application, drug class, and drug type. By application, the market is segmented into heart transplant, kidney transplant, liver transplant, lungs transplant, and others. Further, based on the drug class segment, the market is segmented into calcineurin inhibitors, antiproliferative agents, mTOR inhibitors, steroids, and others. Further, based on drug type, the market is segmented into patented and generic drugs.

Global Immunosuppressive Drug Market Share by Application, 2020 (%)

Global Immunosuppressive Drug Market Share by Application

On the basis of application, the market is segmented into heart transplant, kidney transplant, liver transplant, lungs transplant, and others. The cases for kidney failure is rising frequently that is resulting in kidney transplant. It is expected that kidney transplants will have a considerable share in the market growth. On the basis of drug type, the market is segmented into calcineurin inhibitors, antiproliferative agents, mTOR inhibitors, steroids, and others. Calcineurin inhibitor is expected to have a major market share among all drug types as it is widely used in solid organ transplantation.

Regional Outlooks

The global immunosuppressive drug market is analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. On the basis of geography, the market is divided into North America, Europe, Asia Pacific, and the Rest of the World. North America is estimated to be among the leading region in the market. The market is growing due to rising chronic disease and transplant procedures. Chronic diseases are affecting the organs that will lead to replacing them. The US holds a major market share in the market during the forecast period.

Asia-Pacific will have considerable growth in the global Immunosuppressive Drug Market

Asia-Pacific is estimated to be the fastest-growing market during the forecast period. Several factors are driving the growth of the market such as rising consumption of alcohol that is resulting in damaged liver and kidney as well as a rising chronic disease that is affecting the organs. Moreover, rising government initiatives to reduce the prices of drugs are also motivating factors for the market.

Market Players Outlook

Key players of the immunosuppressive drug market are AbbVie Inc., Astellas Pharma Inc., Bristol-Myers Squibb Co., Cipla Ltd., Dr. Reddy's Laboratories Ltd., F Hoffmann-La Roche Ltd. among others. In order to survive in the market, these players adopt different marketing strategies such as mergers, acquisitions, product launches, and geographical expansion so on. For instance, in November 2020, Lupin Ltd. launched a generic immunosuppressant Tacrolimus capsule in the US after its partnership with Concord Biotech, it received approval for the product from the US healthcare regulator.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global Immunosuppressive Drug Market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. By Application
    • 5.1.1. Heart Transplant
    • 5.1.2. Kidney Transplant
    • 5.1.3. Liver Transplant
    • 5.1.4. Lungs Transplant
    • 5.1.5. Other (Bone Marrow Transplant)
  • 5.2. By Drug Class
    • 5.2.1. Calcineurin Inhibitor
    • 5.2.2. Antiproliferative Agent
    • 5.2.3. mTOR Inhibitors
    • 5.2.4. Steroids
    • 5.2.5. Other
  • 5.3. By Drug Type
    • 5.3.1. Patented
    • 5.3.2. Generic

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbvie Inc.
  • 7.2. Astellas Pharma Inc
  • 7.3. Biocon Ltd.
  • 7.4. Bristol-Myers Squibb Co.
  • 7.5. Cadila Healthcare Ltd.
  • 7.6. Dr. Reddy's Laboratories Ltd.
  • 7.7. F. Hoffmann-La Roche Ltd.
  • 7.8. Intas Pharmaceuticals Ltd (Accord Healthcare Ltd.)
  • 7.9. LGM Pharma, LLC
  • 7.10. Mylan NV
  • 7.11. Novartis AG (Sandoz)
  • 7.12. Pfizer Inc.
  • 7.13. Sanofi SA
  • 7.14. Taj Pharmaceuticals Ltd.
  • 7.15. Topas Therapeutics GmbH
  • 7.16. Teva Pharmaceutical Industries Ltd.
  • 7.17. Veloxis Pharmaceuticals, Inc.